OX40 expression with cGVHD.

(A) Comparison of OX40 expression between patients with cGVHD (n = 11; closed circles and triangles) and without GVHD (n = 11; open circles and triangles). The mean interval between the analysis and SCT is 233 days for patients with cGVHD and 274 days for those without cGVHD. Each bar indicates the mean ± SD in each patient group. (B) Surface phenotype of T cells of a representative case with cGVHD. CD3⁺ T cells were gated and analyzed for expression of OX40, CD25, CD69, and HLA-DR. (C) Serial changes in the percentage of OX40⁺CD4⁺ T cells at 4 different time points around the onset of cGVHD. The first point is the day when patients visited the outpatient clinic 2 months before the onset of GVHD. The second point is the latest visit about 1 month before the onset. The third point is the time point at the onset of cGVHD just before immunosuppressive therapy. The fourth point is the next visit 1 to 2 weeks after the immunosuppressive therapy. The changes between the first 2 points and the comparison between the nonresponders (n = 5; closed point) and the responders (n = 5; open point) at the onset are depicted separately.